Dr. Blaiss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Windfaire Place
Roswell, GA 30076- Is this information wrong?
Education & Training
- Tulane UniversityFellowship, Allergy and Immunology, 1980 - 1982
- University of TennesseeResidency, Pediatrics, 1978 - 1979
- University of TennesseeResidency, Pediatrics, 1977 - 1977
- University of Tennessee Health Science Center College of MedicineClass of 1976
Certifications & Licensure
- GA State Medical License 2012 - 2025
- TN State Medical License 1977 - 2018
- MS State Medical License 2004 - 2016
- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
- Top MD Consumers Checkbook
Publications & Presentations
PubMed
- How to diagnose IgE-mediated food allergy.Jay Lieberman, Antonella Muraro, Michael Blaiss> ;Archives of Disease in Childhood. Education and Practice Edition. 2024 Mar 7
- Sublingual Tablet Immunotherapy Improves Quality of Life in Adults With Allergic Rhinoconjunctivitis.Durham, S., Stranzl, T., Lindholm, M., Nolte, H., Andersen, K., Roberts, G., Blaiss, M., Bernstein, D.> ;The Journal of Allergy and Clinical Immunology. in Practice. 2024 Feb 1
- Real-world effectiveness of dupilumab in patients with asthma: Findings from the US ADVANTAGE study.Michael Blaiss, Eugene R Bleecker, Juby Jacob-Nara, Radhika Nair, Mei Sheng Duh, Zhixiao Wang, Richard H Stanford, Xavier Soler, Megan Hardin, Mingchen Ye, Anamika Kha...> ;Annals of Allergy, Asthma & Immunology. 2024 Apr 1
- Join now to see all
Press Mentions
- U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for AdolescentsJanuary 25th, 2023
- Covid-19: Ciclesonide Failed to Accelerate Recovery in Mild DiseaseNovember 25th, 2021
- COVIS PHARMA GROUP Announces Top-Line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (Ciclesonide)April 15th, 2021
- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
- Baptist Memorial Hospital - MemphisMemphis, Tennessee
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: